Fig. 8 | Nature Communications

Fig. 8

From: LinCCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade

Fig. 8

CCR2+HSCs increase efficacy of PD-1 against brain tumors. a KR158B tumor-bearing GREAT mice were treated with PD-1 and either CCR2HSCs or CCR2+HSCs isolated from either wildtype C57BL/6 mice, MHC I−/− mice, or MHC II−/− mice. Tumors were excised and relative amounts of YFPP+CD3+ cells were measured, specifically between the group that received wildtype CCR2+HSCs and CCR2+HSCs from MHC I−/− (*p < 0.0001, Mann–Whitney, n = 5 mice per group). b KR258B tumor-bearing mice received no treatment, HSC only, PD-1 only, CCR2HSCs, CCR2+HSCs, HSCs+PD-1, CCR2HSCs + PD-1, or CCR2+HSCs + PD-1 (*p = 0.0233, **p = 0.0006). c Ptc medulloblastoma tumor-bearing mice received no treatment, HSC only, PD-1 only, CCR2HSCs, CCR2+HSCs, HSCs + PD-1, CCR2HSCs + PD-1, or CCR2+HSCs + PD-1 (*p = 0.0001, **p = 0.0005). d Mice that received lethal total body irradiation for myeloablative host conditioning received either no treatment, HSCs, CCR2HSCs, or CCR2+HSCs, then followed for survival. e KR158B glioma-bearing mice received adoptive cell therapy (ACT) and either HSCs, CCR2HSCs, or CCR2+HSCs, *p = 0.0005, *n/s p = 0.1776. f Ptc medulloblastoma-bearing mice received adoptive cellular therapy (ACT) and either HSCs or CCR2+HSCs. All error bars represent s.e.m. Comparison of survival data was conducted with Gehan–Breslow–Wilcoxon test

Back to article page